Testosterone is significantly correlated with aggression and competitive behaviour and is directly facilitated by the latter. There are two theories on the role of testosterone in aggression and competition.  The first one is the challenge hypothesis which states that testosterone would increase during puberty thus facilitating reproductive and competitive behaviour which would include aggression.  Thus it is the challenge of competition among males of the species that facilitates aggression and violence.  Studies conducted have found direct correlation between testosterone and dominance especially among the most violent criminals in prison who had the highest testosterone levels.  The same research also found fathers (those outside competitive environments) had the lowest testosterone levels compared to other males. 
Hi Caroline. Professor Studd is quite unusual in prescribing Utrogestan for such a short period as this can be more risky in terms of thickened endometrial lining. I think he does this so that women can avoid the symptoms of progesterone intolerance. The standard recommendation is that progesterone be taken for 12-14 days a month. This is to ensure that you have a proper bleed and all the endometrial lining is shed. If you take Utrogestan for only 7 days a month you will need to be closely monitored for thickening of your endometrial lining by having more frequent vaginal ultrasounds. Professor Studd usually advises women to start taking Utrogestan on the 1st day of the calendar month as this is the simplest procedure, so you could try that. You could try and work out your cycle based on the date of your last period or if you have already started taking the EstroGel, opt for any day. If you haven’t already started, start the EstroGel and count day one of EstroGel as day one of your cycle and then start the Utrogestan on day 12. I hope that helps.
The primary endpoint was the percentage of patients with C avg within the normal range (greater than or equal to 300 ng/dL and less than or equal to 1140 ng/dL) on Day 90. In patients treated with FORTESTA, % (100/129) had C avg within the normal range on Day 90. The secondary endpoint was the percentage of patients with C max above three pre-determined limits. The percentages of patients with C max greater than 1500 ng/dL, and between 1800 and 2499 ng/dL on Day 90 were % and %, respectively. No patient had a C max greater than or equal to 2500 ng/dL on Day 90.